https://www.oleandermedicaltechnologies.com/unmetneed daily 0.75 2025-02-27 https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1607143119692-F0T9BKH0X8RDXS33R8CC/sideeffects.png Unmet Need https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1607141769829-8X6VLATIVZOPNMRGCY2T/stagesofcancer.png Unmet Need https://www.oleandermedicaltechnologies.com/team daily 0.75 2025-02-27 https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1607107517481-JYT1PRZ7II4T16EMT6I5/t-l-paige.png Team - Paige R. Miller, J.D. Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1607107548697-GB07VWOEHYEOFD28DTLO/t-l-dennis.png Team - Dennis Paul, Ph.D. Chief Science Officer Dr. Paul is co-inventor with Dr. Gould of Targeted Osmotic Lysis (TOL). He is Professor of Pharmacology and Experimental Therapeutics at Louisiana State University Health Sciences Center (LSUHSC) in New Orleans. Drs. Paul and Gould have had a research collaboration for more than 20 years. Their work initially focused on general concepts and biological principles related to the role played by sodium channels in the mechanisms responsible for pain and diabetic peripheral neuropathy. Their research on sodium channels and sodium pumps led directly to their research on manipulation of these mechanisms in the treatment of advanced cancer. Dr. Paul's research has also contributed to the understanding of opioid pharmacology and drug-drug interactions. He received his undergraduate training at the University of Cincinnati, his Ph.D. from the University of British Columbia, and completed Post-Doctoral training at the Memorial Sloan Kettering Cancer Center. He has served on scientific advisory boards for Xanadyne Pharmaceuticals and St. Charles Pharmaceuticals. https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1607107585285-I98L17TCNNUG0KMH4ZKJ/t-l-harry.png Team - Harry J. Gould, III, M.D., Ph.D. Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1607107633013-PW18EYBZ66ND3S3Z35AR/t-l-hank.png Team - Hank Mills Chief Financial Officer Mr. Mills has 35 years of experience as a serial entrepreneur, including taking a medical device from the “napkin stage” through development, FDA approval, Medicare code approval, marketing, launch, and successful exit. His other ventures include software development, wetlands banking, and portable storage units. He is a graduate of Louisiana State University in finance. He has previously been a licensed stock broker and financial advisor. His experience in fundraising, marketing, and launching products provides expertise in raising capital, creating strategic alliances, and aggressively pursuing product and commercial development. https://www.oleandermedicaltechnologies.com/milestones daily 0.75 2025-07-04 https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1608319396739-ZM1HXUFZESYU98D6IO7P/tissueculture.png Milestones - Tissue culture 2013: Dr. Paul and Dr. Gould released a poster presentation for the American Society for Cell Biology Annual Meeting, outlining the basic principles of TOL. 2014: TOL achieved 95%-100% lysis in tissue culture, including lung, breast, colon, prostate and pancreatic cancer. Early experiments demonstrated that over 80% of cancer cells could be killed in a single pass, while leaving healthy cells unharmed. https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1607118863875-V1CLFMJGTNFOVW4F4O99/Screen+Shot+2020-12-04+at+1.52.59+PM.png Milestones - Mice 2017: Oleander developed its first electrical device, a solenoid coil with ice water bath for treating cancer in mice. 2019: Mouse survival studies showed that TOL could reduce nominal tumor size by 50% within 48 hours, and double survival time in mice inoculated with TN breast cancer. 2020: After progressing from the solenoid ring to a coaxial ring, further studies on mice indicated reduction of nominal tumor size by 55% within 24 hours. TOL was able to completely eliminate mesothelioma tumors in mice. https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1607118941369-YGPBIH2S9MLW8HVGR4EV/Dog+safety+trial+in+toroid+II.jpg Milestones - Companion animals TOL has been safety tested in dogs and cats and has been used under the supervision of veterinarians in Louisiana as a treatment for advanced cancer. To date more than 40 companion animals have been treated without serious side effects, and none have exhibited any discomfort, pain or harm due to the treatment. Some highlights: 2019: Early safety testing on cats and dogs, beginning with a toroid device, was conducted at LSU School of Veterinary Medicine and was found to cause no harm. 2020: Ongoing pilot clinical studies have consistently reduced tumor size in companion animals. The first canine patient, Gizmo, a Maltese mix with facial carcinoma, experienced tumor reduction of 15-20% over six treatments. Robert, the first feline patient, also exhibited significant tumor reduction of advanced adenocarcinoma. 2021: Pilot studies in dogs and cats in veterinary clinics continued in Metairie, Louisiana and began in Mandeville, Louisiana. Dodge, an English Shepherd with bronchoalveolar lung cancer, was treated with TOL for 7½ months. The tumor was kept from growing, and when the dog was euthanized for severe arthritis, the necropsy found that the tumor was 90% necrotic (dead). Marley, a Labrador Retriever with a nasal carcinoma, began treatment in early December 2021. The very large tumor disappeared and histopathology showed no evidence of it 17 months later. Marley lived until December 2024, three years after first treatment. Her nasal carcinoma never returned. 2022: Otto, a Rottweiler with bladder cancer, had a prognosis of 2-3 months to live when he began treatment in late July 2022. More than 9 months later he was still alive, and the tumor was smaller than when first diagnosed. 2023: Working under FDA guidance, Oleander began a toxicology study in dogs to demonstrate safety of TOL. This study was completed in 2024. See Article > https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/d55d0160-35f8-4938-ba2a-b3c6c4286133/Marley22.png Milestones - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1607119545724-LTOH0T2MV2LO5K4UT8IN/Screen+Shot+2020-12-04+at+2.04.48+PM.png Milestones - Human clinical trials 2020: Manufacture and delivery of full size coaxial ring gives Oleander the capability of treating human patients. 2022: A second human-sized device was manufactured and delivered to the Oleander team. 2024: Human pilot studies for patients with advanced cancer began in January at a location offshore. 2025: Human pilot studies began at a hospital in Mexico. https://www.oleandermedicaltechnologies.com/procedure daily 0.75 2021-01-22 https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1607140161597-YDIPTZ7H8PNS6FCJ1W6K/devices.png Procedure https://images.squarespace-cdn.com/content/v1/5fc5557d11f6a41984a3238a/1608166759303-2FP4O6V6BT5OKIDU4DXW/processforanimals-clear.png Procedure https://www.oleandermedicaltechnologies.com/principles daily 0.75 2020-12-29 https://www.oleandermedicaltechnologies.com/faq daily 0.75 2025-02-27 https://www.oleandermedicaltechnologies.com/news daily 0.75 2025-07-04 https://www.oleandermedicaltechnologies.com/contact daily 0.75 2025-02-27 https://www.oleandermedicaltechnologies.com/home daily 1.0 2024-01-25 https://www.oleandermedicaltechnologies.com/comingsoon daily 0.75 2021-01-21 https://www.oleandermedicaltechnologies.com/thankyou daily 0.75 2021-01-21 https://www.oleandermedicaltechnologies.com/privacy daily 0.75 2021-01-23 https://www.oleandermedicaltechnologies.com/404error daily 0.75 2021-01-23 https://www.oleandermedicaltechnologies.com/research daily 0.75 2025-07-04